Free Trial

Hyperion DeFi (HYPD) Competitors

Hyperion DeFi logo
$13.23 +0.64 (+5.08%)
As of 07/11/2025 04:00 PM Eastern

HYPD vs. CYBN, TIL, PBYI, VYGR, TLSA, IMAB, LFVN, ENTA, IPHA, and ACOG

Should you be buying Hyperion DeFi stock or one of its competitors? The main competitors of Hyperion DeFi include Cybin (CYBN), Instil Bio (TIL), Puma Biotechnology (PBYI), Voyager Therapeutics (VYGR), Tiziana Life Sciences (TLSA), I-Mab (IMAB), Lifevantage (LFVN), Enanta Pharmaceuticals (ENTA), Innate Pharma (IPHA), and Alpha Cognition (ACOG). These companies are all part of the "pharmaceutical products" industry.

Hyperion DeFi vs. Its Competitors

Hyperion DeFi (NASDAQ:HYPD) and Cybin (NYSE:CYBN) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their media sentiment, dividends, analyst recommendations, earnings, profitability, valuation, institutional ownership and risk.

Hyperion DeFi presently has a consensus price target of $2.00, indicating a potential downside of 84.88%. Cybin has a consensus price target of $85.00, indicating a potential upside of 1,012.57%. Given Cybin's stronger consensus rating and higher probable upside, analysts plainly believe Cybin is more favorable than Hyperion DeFi.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Hyperion DeFi
0 Sell rating(s)
4 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00
Cybin
0 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
1 Strong Buy rating(s)
3.25

Hyperion DeFi has a beta of 2.47, indicating that its share price is 147% more volatile than the S&P 500. Comparatively, Cybin has a beta of 0.69, indicating that its share price is 31% less volatile than the S&P 500.

25.8% of Hyperion DeFi shares are owned by institutional investors. Comparatively, 17.9% of Cybin shares are owned by institutional investors. 7.1% of Hyperion DeFi shares are owned by company insiders. Comparatively, 15.0% of Cybin shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Hyperion DeFi has higher revenue and earnings than Cybin. Cybin is trading at a lower price-to-earnings ratio than Hyperion DeFi, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Hyperion DeFi$60K635.04-$49.82M-$58.40-0.23
CybinN/AN/A-$57.88M-$3.88-1.97

Cybin has a net margin of 0.00% compared to Hyperion DeFi's net margin of -62,238.41%. Hyperion DeFi's return on equity of 0.00% beat Cybin's return on equity.

Company Net Margins Return on Equity Return on Assets
Hyperion DeFi-62,238.41% N/A -316.90%
Cybin N/A -37.58%-36.59%

In the previous week, Cybin had 3 more articles in the media than Hyperion DeFi. MarketBeat recorded 4 mentions for Cybin and 1 mentions for Hyperion DeFi. Cybin's average media sentiment score of 0.54 beat Hyperion DeFi's score of 0.00 indicating that Cybin is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Hyperion DeFi
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Cybin
0 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

Cybin beats Hyperion DeFi on 10 of the 16 factors compared between the two stocks.

Get Hyperion DeFi News Delivered to You Automatically

Sign up to receive the latest news and ratings for HYPD and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding HYPD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

HYPD vs. The Competition

MetricHyperion DeFiBiotechnology IndustryMedical SectorNASDAQ Exchange
Market Cap$36.29M$129.37M$5.61B$9.11B
Dividend YieldN/A3.74%5.24%4.02%
P/E Ratio-0.233.4727.9620.25
Price / Sales635.044,141.03430.8999.65
Price / CashN/A13.1937.4658.16
Price / Book-0.0242.088.045.49
Net Income-$49.82M-$92.15M$3.18B$250.27M
7 Day Performance-17.11%1.27%3.67%4.80%
1 Month Performance395.51%4.30%4.09%7.68%
1 Year Performance-84.54%174.69%29.58%16.36%

Hyperion DeFi Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
HYPD
Hyperion DeFi
0.6051 of 5 stars
$13.23
+5.1%
$2.00
-84.9%
-83.4%$36.29M$60K-0.2340Gap Up
CYBN
Cybin
2.8132 of 5 stars
$7.87
-0.9%
$86.00
+992.8%
N/A$181.20MN/A-1.8050Analyst Forecast
TIL
Instil Bio
3.3715 of 5 stars
$23.64
-14.0%
$119.00
+403.4%
+152.5%$180.37MN/A-1.97410Positive News
Gap Down
High Trading Volume
PBYI
Puma Biotechnology
4.218 of 5 stars
$3.54
-1.1%
$7.00
+97.7%
-1.5%$177.68M$230.50M4.60200Trending News
VYGR
Voyager Therapeutics
3.983 of 5 stars
$3.04
-5.0%
$13.39
+340.5%
-61.0%$177.08M$80M-2.08100
TLSA
Tiziana Life Sciences
1.3434 of 5 stars
$1.53
+1.3%
N/A+80.5%$176.44MN/A0.008News Coverage
IMAB
I-Mab
2.9205 of 5 stars
$2.09
-2.8%
$6.00
+187.1%
+34.8%$175.57M$3.89M0.00380Analyst Forecast
Gap Up
LFVN
Lifevantage
4.3321 of 5 stars
$13.59
-0.9%
$30.50
+124.4%
+99.8%$172.71M$200.16M19.70260
ENTA
Enanta Pharmaceuticals
3.9118 of 5 stars
$7.65
-3.0%
$18.00
+135.3%
-56.2%$168.66M$67.64M-1.69160
IPHA
Innate Pharma
2.6257 of 5 stars
$1.79
-1.6%
$11.00
+514.5%
-17.0%$167.76M$21.77M0.00220
ACOG
Alpha Cognition
1.6389 of 5 stars
$11.24
+7.4%
$20.00
+77.9%
N/A$167.65MN/A-9.37N/AGap Up

Related Companies and Tools


This page (NASDAQ:HYPD) was last updated on 7/12/2025 by MarketBeat.com Staff
From Our Partners